Table 2.
Absolute values of PET/CT parameters during treatment of patients with relapsed/refractory diffuse large B-cell lymphoma (n = 55) using bendamustine–rituximab
| Baseline | Two cycles | Last cycle | |
|---|---|---|---|
| LD, mm | 38.8 ± 3.5 | 31.8 ± 4.3 | 29.9 ± 5.5 |
| SPD, mm2 (×102) | 15.2 ± 3.1 | 14.9 ± 4.0 | 15.5 ± 6.2 |
| SUVmax, g/mL | 15.0 ± 1.1 | 6.3 ± 1.0 | 6.8 ± 1.2 |
| SUL, g/mL | 12.4 ± 1.1 | 5.3 ± 0.9 | 5.6 ± 1.0 |
| MTV, mm3 (×101) | 66.1 ± 14.5 | 34.7 ± 13.4 | 41.7 ± 10.9 |
| ΣMTV, mm3 (×101) | 105.8 ± 23.2 | 59.1 ± 22.7 | 75.1 ± 19.6 |
| TLG, g (×101) | 105.5 ± 23.2 | 61.4 ± 21.7 | 52.3 ± 16.3 |
| ΣTLG, g (×101) | 173.1 ± 38.1 | 108.7 ± 38.4 | 97.7 ± 30.4 |
| AUC-CSH (×10−1) | 5.2 ± 0.7 | 5.3 ± 0.8 | 5.3 ± 0.2 |
AUC-CSH, area under the curve of cumulative standardized uptake value (SUV)–volume histogram; LD, largest diameter; MTV, metabolic tumor volume; ΣMTV, sum of MTV for a maximum of six target lesions per patient; SPD, sum of products of the maximum perpendicular diameters; SUL, peak value of SUVmax corrected for the lean body mass; SUVmax, maximum SUV; TLG, total lesion glycolysis; ΣTLG, sum of TLG for a maximum of six target lesions per patient.